Sotatercept: New Therapies for PAH

Pulmonary arterial hypertension (PAH) remains a devastating, progressive disease with high morbidity and mortality despite advances in targeted therapies. Sotatercept, the most recent addition to the PAH treatment landscape, has demonstrated robust efficacy across multiple phase 3 randomized clinical trials. The HYPERION trial expands the evidence base by showing a favorable benefit–risk profile for sotatercept when used early in the disease course. Pooled analyses across trials further suggest that sotatercept may have a meaningful impact on mortality in patients with PAH.

In this interview, Mary Norine Walsh MD, MACC and Vallerie V. McLaughlin, MD, FACC discuss the phase 3 HYPERION trial.